 AVROBIO Inc NASDAQ: AVRO reported new interim data from the Phase 12 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cystine a building block of proteins within cells. 